Cole Susan P C, Deeley Roger G
Division of Cancer Biology and Genetics, Cancer Research Institute, Queen's University, Kingston, Ontario K7L 3N6, Canada.
Trends Pharmacol Sci. 2006 Aug;27(8):438-46. doi: 10.1016/j.tips.2006.06.008. Epub 2006 Jul 3.
Glutathione (GSH)-conjugated xenobiotics and GSH-conjugated metabolites (e.g. the cysteinyl leukotriene C4) must be exported from the cells in which they are formed before they can be eliminated from the body or act on their cellular targets. This efflux is often mediated by the multidrug resistance protein 1 (MRP1) transporter, which also confers drug resistance to tumour cells and can protect normal cells from toxic insults. In addition to drugs and GSH conjugates, MRP1 exports GSH and GSH disulfide, and might thus have a role in cellular responses to oxidative stress. The transport of several drugs and conjugated organic anions by MRP1 requires the presence of GSH, but it is not well understood how GSH (and its analogues) enhances transport. Site-directed mutagenesis studies and biophysical analyses have provided important insights into the structural determinants of MRP1 that influence GSH and GSH conjugate binding and transport.
谷胱甘肽(GSH)结合的外源性物质和GSH结合的代谢产物(如半胱氨酰白三烯C4)在能够从体内清除或作用于其细胞靶点之前,必须从生成它们的细胞中输出。这种外排通常由多药耐药蛋白1(MRP1)转运体介导,该转运体也赋予肿瘤细胞耐药性,并能保护正常细胞免受毒性损伤。除了药物和GSH结合物外,MRP1还输出GSH和GSH二硫化物,因此可能在细胞对氧化应激的反应中发挥作用。MRP1对几种药物和结合有机阴离子的转运需要GSH的存在,但目前尚不清楚GSH(及其类似物)如何增强转运。定点诱变研究和生物物理分析为影响GSH和GSH结合物结合及转运的MRP1结构决定因素提供了重要见解。